Vicarious Surgical Inc. WT
RBOT-WT
New York Stock Exchange0.01
USD
+0.00
- -
CIK
0001812173
ISIN
US92561V1171
Return %
Stock
S&P500
1Y
-65.98
26.53
3Y
-91.80
76.60
5Y
-91.80
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam David Sachs
- Full Time Employees
- 123
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 78 Fourth Avenue Waltham MA United States of America 02451
- CIK
- 0001812173
- Website
- vicarioussurgical.com
- Similar Companies
- Business
- Vicarious Surgical Inc. (NYSE: RBOT, RBOT-WT) develops next-generation robotics technology for minimally invasive surgery, featuring the Vicarious Surgical System that integrates miniaturized human-like robotic arms, immersive 3D high-definition visualization, and a virtual reality surgeon console to enable single-port access through a 1.5 cm incision. The system offers wristed instruments with 28 sensors per arm for human-inspired motion, adaptive control, 360-degree visibility, and full internal operation to enhance precision, dexterity, and efficiency across specialties including general surgery, gynecology, urology, and ventral hernia procedures; it also provides comprehensive training programs, service contracts, and remote support for hospitals. Founded in 2014 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States, with plans for international regulatory approvals, and received FDA Breakthrough Device Designation for its robot. Recent developments include a May 2025 partnership with UMass Memorial Medical Center to advance clinical adoption, patient treatments, and surgeon education ahead of a late 2026 FDA de novo submission; a $10 million financing round completed in late 2025 to support VR surgical robot advancement; and a December 2025 announcement reducing full-year 2025 cash burn outlook to $45 million from $50 million through cost management and operational reset, alongside board committee realignments. Backed by investors such as Bill Gates and Khosla Ventures, Vicarious Surgical focuses on reducing patient trauma, shortening recovery times, and expanding global access to advanced care via its disruptive single-port platform.